# US 9,107,892 B2 · Identification of a novel retrovirus in patients with benign prostatic hyperplasia

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,107,892 B2
- Document ID: US9107892B2
- Status: Granted
- Kind: B2
- Application number: 13/282,888
- Filed: 2011-10-27
- Published: 2012-05-03
- Granted: 2015-08-18
- Earliest claimed: 2010-10-28
- Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education
- Applicants: Denise S. O'Keefe
- Inventors: Denise S. O'Keefe
- Web page: https://patentgrep.com/patent/US9107892B2

## CPC

- A61K 39/21: Retroviridae, e.g. equine infectious anemia virus
- A61K 39/12: Viral antigens
- A61P 31/14: for RNA viruses
- A61P 37/04: Immunostimulants
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12Q 1/701: {Specific hybridization probes}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C12N 2740/13011: Gammaretrovirus, e.g. murine leukeamia virus
- C12N 2740/13021: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2740/13022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2740/13034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12Q 1/00: Measuring or testing processes involving enzymes, nucleic acids or microorganisms (measuring or testing apparatus with condition measuring or sensing means, e.g. colony counters, C12M1/34); Compositions therefor; Processes of preparing such compositions
- C12Q 1/6844: Nucleic acid amplification reactions
- C12Q 1/6846: {Common amplification features}
- C12Q 1/686: Polymerase chain reaction [PCR]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Methods for producing an immune response to a benign prostatic hyperplasia (BPH) virus are disclosed herein. In several examples, the immune response is a protective immune response. In additional embodiments, methods are disclosed for inhibiting an infection with BPH virus, or treating an infection with BPH virus. Also disclosed are methods for detecting presence of BPH virus in a subject. The methods include detecting the presence of one or more BPH virus polynucleotides or polypeptides in a sample from the subject, or presence of at least one antibody that specifically binds to a BPH virus polypeptide.

## Claims

### Claim 1

A method of detecting benign prostatic hyperplasia (BPH) virus in a human subject, comprising:
contacting a sample obtained from the human subject with a detectably labeled probe comprising the nucleic acid sequence of SEQ ID NO: 73 or SEQ ID NO: 74, a forward primer comprising the nucleic acid sequence of SEQ ID NO: 71 and a reverse primer comprising the nucleic acid sequence of SEQ ID NO: 72;
carrying out real-time PCR; and
detecting the detectably labeled probe, thereby detecting presence of BPH virus in the human subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the sample obtained from the subject comprises prostate tissue.

### Claim 3 (depends on 1)

The method of claim 1, wherein presence of BPH virus in the subject indicates the subject has BPH or is at risk of BPH.

### Claim 4 (depends on 3)

The method of claim 3, further comprising selecting a therapy for the subject.